Maria Domenica Cappellini

List of Publications by Year
in descending order

392	20,834	10979	14197
papers	citations	71 h-index	128 g-index

399	399	399	14742
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Morbidity-free survival and hemoglobin level in non-transfusion-dependent Î²-thalassemia: a 10-year cohort study. Annals of Hematology, 2022, 101, 203-204.	0.8	21
2	Thalassemia and autoimmune diseases: Absence of evidence or evidence of absence?. Blood Reviews, 2022, 52, 100874.	2.8	6
3	Italian patients with hemoglobinopathies exhibit a 5â€fold increase in ageâ€standardized lethality due to SARSâ€CoVâ€2 infection. American Journal of Hematology, 2022, 97, .	2.0	7
4	Mortality in Î²-thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization. Blood, 2022, 139, 2080-2083.	0.6	10
5	Tricuspid-valve regurgitant jet velocity as a risk factor for death in Î²-Thalassemia. Haematologica, 2022, , .	1.7	0
6	Thalassaemia is paradoxically associated with a reduced risk of inâ€hospital complications and mortality in COVIDâ€19: Data from an international registry. Journal of Cellular and Molecular Medicine, 2022, 26, 2520-2528.	1.6	6
7	Splenomegaly: Dare to think rare. American Journal of Hematology, 2022, 97, 1259-1265.	2.0	1
8	Redox Balance in Î²-Thalassemia and Sickle Cell Disease: A Love and Hate Relationship. Antioxidants, 2022, 11, 967.	2.2	5
9	An openâ€label, multicenter, efficacy, and safety study of deferasirox in ironâ€overloaded patients with nonâ€transfusionâ€dependent thalassemia (<scp>THETIS</scp>): 5â€year results. American Journal of Hematology, 2022, 97, .	2.0	2
10	Pharmacological Induction of Fetal Hemoglobin in Î²-Thalassemia and Sickle Cell Disease: An Updated Perspective. Pharmaceuticals, 2022, 15, 753.	1.7	14
11	CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Î²-Thalassemia. New England Journal of Medicine, 2021, 384, 252-260.	13.9	939
12	Revisiting the nonâ€transfusionâ€dependent (NTDT) vs. transfusionâ€dependent (TDT) thalassemia classification 10 years later. American Journal of Hematology, 2021, 96, E54-E56.	2.0	28
13	Î²-Thalassemias. New England Journal of Medicine, 2021, 384, 727-743.	13.9	183
14	Ferric carboxymaltose for sub-acute and chronic iron deficiency anemia in inherited platelet function defects. Internal and Emergency Medicine, 2021, 16, 505-507.	1.0	2
15	CYP450 Mediates Reactive Oxygen Species Production in a Mouse Model of Î²-Thalassemia through an Increase in 20-HETE Activity. International Journal of Molecular Sciences, 2021, 22, 1106.	1.8	6
16	The use of luspatercept for thalassemia in adults. Blood Advances, 2021, 5, 326-333.	2.5	28
17	Variations in hemoglobin level and morbidity burden in non-transfusion-dependent Î²-thalassemia. Annals of Hematology, 2021, 100, 1903-1905.	0.8	20
18	Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with nonâ€transfusionâ€dependent Î²â€thalassaemia. British Journal of Haematology, 2021, 194, 474-477.	1.2	10

#	Article	IF	Citations
19	Innovative Treatments for Rare Anemias. HemaSphere, 2021, 5, e576.	1.2	13
20	The EHA Research Roadmap: Anemias. HemaSphere, 2021, 5, e607.	1.2	7
21	Muscular deâ€conditioning and reduced cardiac inotropism due to iron deposition reduce exercise tolerance in beta thalassemia major. American Journal of Hematology, 2021, 96, E370-E373.	2.0	1
22	Expertsâ€™ views on COVIDâ€19 vaccination and the impact of the pandemic on patients with Gaucher disease. British Journal of Haematology, 2021, 195, e135-e137.	1.2	3
23	Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in Î²-thalassemia: current evidence and future clinical development. Expert Review of Hematology, 2021, 14, 633-644.	1.0	13
24	2021 update on clinical trials in Î²â€thalassemia. American Journal of Hematology, 2021, 96, 1518-1531.	2.0	38
25	Luspatercept for Î²-thalassemia: beyond red blood cell transfusions. Expert Opinion on Biological Therapy, 2021, 21, 1363-1371.	1.4	14
26	Improving outcomes and quality of life for patients with transfusion-dependent Î²-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies. Expert Review of Hematology, 2021, 14, 897-909.	1.0	13
27	Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia. Scientific Reports, 2021, 11, 2594.	1.6	12
28	Changing patterns of thalassaemia in Italy: a WebThal perspective. Blood Transfusion, 2021, 19, 261-268.	0.3	2
29	Inhibition of Fibroblast Growth Factor-23 (FGF-23) Rescues Bone and Hematopoietic Stem Cell Niche Defects in Beta-Thalassemia, Uncovering the Missing Link between Hematopoiesis and Bone. Blood, 2021, 138, 572-572.	0.6	1
30	Luspatercept Improves Quality of Life and Reduces Red Blood Cell Transfusion Burden in Patients with Non-Transfusion-Dependent Î²-Thalassemia in the BEYOND Trial. Blood, 2021, 138, 3081-3081.	0.6	4
31	Kidney Tubular Damage Secondary to Deferasirox: Systematic Literature Review. Children, 2021, 8, 1104.	0.6	7
32	Advancing the care of Î²-thalassaemia patients with novel therapies. Blood Transfusion, 2021, , .	0.3	1
33	Treatment with ferric carboxymaltose in stable patients with severe iron deficiency anemia in the emergency department. Internal and Emergency Medicine, 2020, 15, 629-634.	1.0	12
34	Management of age-associated medical complications in patients with Î²-thalassemia. Expert Review of Hematology, 2020, 13, 85-94.	1.0	18
35	Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment?. Expert Opinion on Investigational Drugs, 2020, 29, 23-31.	1.9	15
36	A new approach for anemia in kidney disease. European Journal of Internal Medicine, 2020, 71, 1-3.	1.0	3

#	Article	IF	Citations
37	Parkinsonâ€™s disease in Gaucher disease patients: whatâ€™s changing in the counseling and management of patients and their relatives?. Orphanet Journal of Rare Diseases, 2020, 15, 262.	1.2	3
38	Fyn specifically Regulates the activity of red cell glucose-6-phosphate-dehydrogenase. Redox Biology, 2020, 36, 101639.	3.9	14
39	Clinical and molecular epidemiology of erythropoietic protoporphyria in Italy. European Journal of Dermatology, 2020, 30, 532-540.	0.3	10
40	Inherited microcytic anemias. Hematology American Society of Hematology Education Program, 2020, 2020, 465-470.	0.9	12
41	Recommendations for Pregnancy in Rare Inherited Anemias. HemaSphere, 2020, 4, e446.	1.2	8
42	Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease. Liver International, 2020, 40, 3061-3070.	1.9	13
43	A holistic approach to iron chelation therapy in transfusionâ€dependent thalassemia patients with serum ferritin below 500â€‰Î¼g/L. American Journal of Hematology, 2020, 95, E230-E232.	2.0	2
44	Care of patients with hemoglobin disorders during the <scp>COVID</scp>â€19 pandemic: An overview of recommendations. American Journal of Hematology, 2020, 95, E208-E210.	2.0	24
45	Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation. Drugs, 2020, 80, 1053-1063.	4.9	49
46	A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent Î²-Thalassemia. New England Journal of Medicine, 2020, 382, 1219-1231.	13.9	177
47	Hyperferritinemia and diagnosis of type 1 Gaucher disease. American Journal of Hematology, 2020, 95, 570-576.	2.0	6
48	Less â€˜redsâ€™ more â€˜bluesâ€™: hemoglobin level and depression in non-transfusion-dependent thalassemia. Annals of Hematology, 2020, 99, 903-904.	0.8	9
49	Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist. Digestive and Liver Disease, 2020, 52, 368-373.	0.4	15
50	<scp>SARSâ€CoV</scp>â€2 infection in beta thalassemia: Preliminary data from the Italian experience. American Journal of Hematology, 2020, 95, E198-E199.	2.0	56
51	Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial. Blood, 2020, 136, 8-9.	0.6	7
52	Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with Î²-Thalassemia in the Believe Trial. Blood, 2020, 136, 47-48.	0.6	8
53	Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in Î²-Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial. Blood, 2020, 136, 45-46.	0.6	8
54	Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited. Internal and Emergency Medicine, 2019, 14, 365-370.	1.0	13

#	Article	IF	Citations
55	Quality of life in patients with Î²â€thalassemia: A prospective study of transfusionâ€dependent and nonâ€transfusionâ€dependent patients in Greece, Italy, Lebanon, and Thailand. American Journal of Hematology, 2019, 94, E261-E264.	2.0	21
56	UGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemia. American Journal of Hematology, 2019, 94, E283-E285.	2.0	4
57	Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ÃŸ-thalassemia. Nature Medicine, 2019, 25, 234-241.	15.2	188
58	Current challenges in the management of patients with sickle cell disease â€“ A report of the Italian experience. Orphanet Journal of Rare Diseases, 2019, 14, 120.	1.2	24
59	Oocyte quality in women with thalassaemia major: insights from IVF cycles. European Journal of Obstetrics and Gynecology and Reproductive Biology: X, 2019, 3, 100048.	0.6	6
60	Development of a thalassemiaâ€related thrombosis risk scoring system. American Journal of Hematology, 2019, 94, E207-E209.	2.0	7
61	Iron overload in congenital haemolytic anaemias: role of hepcidin and cytokines and predictive value of ferritin and transferrin saturation. British Journal of Haematology, 2019, 185, 523-531.	1.2	6
62	Diagnosis of chronic anaemia in gastrointestinal disorders: A guideline by the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) and the Italian Society of Paediatric Gastroenterology Hepatology and Nutrition (SIGENP). Digestive and Liver Disease, 2019, 51, 471-483.	0.4	21
63	EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update. HemaSphere, 2019, 3, e208.	1.2	13
64	Development of a patientâ€reported outcomes symptom measure for patients with nontransfusionâ€dependent thalassemia (NTDTâ€PRO^{Â©}). American Journal of Hematology, 2019, 94, 171-176.	2.0	7
65	Validation of a patientâ€reported outcomes symptom measure for patients with nontransfusionâ€dependent thalassemia (NTDTâ€PRO^{Â©}). American Journal of Hematology, 2019, 94, 177-183.	2.0	7
66	Sotatercept, a novel transforming growth factor Î² ligand trap, improves anemia in Î²-thalassemia: a phase II, open-label, dose-finding study. Haematologica, 2019, 104, 477-484.	1.7	61
67	Common fetal hemoglobin variants in Lebanese patients bearing the codon 29 beta gene mutation associated with different thalassemia phenotypes. Annals of Hematology, 2019, 98, 833-840.	0.8	0
68	Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial. Blood, 2019, 134, 2245-2245.	0.6	7
69	Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions. Blood, 2019, 134, 3545-3545.	0.6	3
70	Selecting ÃŸ-Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm. Blood, 2019, 134, 972-972.	0.6	2
71	Microcytosis is important in screening of iron deficiency anemia. European Journal of Internal Medicine, 2018, 48, e39.	1.0	0
72	A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?. Blood Reviews, 2018, 32, 300-311.	2.8	95

#	Article	IF	Citations
73	Hypercoagulability and Vascular Disease. Hematology/Oncology Clinics of North America, 2018, 32, 237-245.	0.9	20
74	Clinical Complications and Their Management. Hematology/Oncology Clinics of North America, 2018, 32, 223-236.	0.9	14
75	Low-dose Synachten test with measurement of salivary cortisol in adult patients with Î²-thalassemia major. Endocrine, 2018, 60, 348-354.	1.1	5
76	An unusual diagnosis in a 31-year-old man with abdominal pain and hyponatremia. Internal and Emergency Medicine, 2018, 13, 1233-1238.	1.0	0
77	Thalassaemia. Lancet, The, 2018, 391, 155-167.	6.3	512
78	What is behind a relapse of thrombotic thrombocytopenic purpura?. Internal and Emergency Medicine, 2018, 13, 709-712.	1.0	1
79	Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent. Blood Cells, Molecules, and Diseases, 2018, 69, 82-89.	0.6	34
80	How I manage medical complications of Î²-thalassemia in adults. Blood, 2018, 132, 1781-1791.	0.6	78
81	Nonâ€transferrinâ€bound iron and oxidative stress during allogeneic hemopoietic stem cell transplantation in patients with or without iron overload. American Journal of Hematology, 2018, 93, E250-E252.	2.0	15
82	Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management. International Journal of Molecular Sciences, 2018, 19, 182.	1.8	46
83	Circulating cellâ€free DNA and ineffective erythropoiesis in nontransfusionâ€dependent Î²â€thalassemia. American Journal of Hematology, 2018, 93, E365-E368.	2.0	2
84	Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease. Molecular Genetics and Metabolism, 2018, 125, 64-72.	0.5	18
85	Role of T1 mapping as a complementary tool to T2* for non-invasive cardiac iron overload assessment. PLoS ONE, 2018, 13, e0192890.	1.1	51
86	The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 163-163.	0.6	11
87	Sickle cell maculopathy: Identification of systemic risk factors, and microstructural analysis of individual retinal layers of the macula. PLoS ONE, 2018, 13, e0193582.	1.1	22
88	The role of cardiac magnetic resonance in assessing the cardiac involvement in Gaucher type 1 patients. Journal of Cardiovascular Medicine, 2017, 18, 244-248.	0.6	9
89	Reply to Management of hepatocellular carcinoma in thalassemia and importance of the human factor. Cancer, 2017, 123, 1073-1073.	2.0	1
90	Anemia is a mortality prognostic factor in patients initially hospitalized for acute heart failure. Internal and Emergency Medicine, 2017, 12, 749-756.	1.0	27

#	Article	IF	Citations
91	Pregnancy in Î²â€thalassemia intermedia at two tertiary care centers in Lebanon and Italy: A followâ€up report on fetal and maternal outcomes. American Journal of Hematology, 2017, 92, E96-E99.	2.0	6
92	Hematologic malignancies in thalassemia: Adding new cases to the repertoire. American Journal of Hematology, 2017, 92, E68-E70.	2.0	6
93	A higher prevalence of hematologic malignancies in patients with thalassemia: Background and culprits. American Journal of Hematology, 2017, 92, 414-416.	2.0	11
94	Myocardial deformation in iron overload cardiomyopathy: speckle tracking imaging in a beta-thalassemia major population. Internal and Emergency Medicine, 2017, 12, 799-809.	1.0	30
95	Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review. Cancer, 2017, 123, 751-758.	2.0	54
96	Iron overload across the spectrum of nonâ€transfusionâ€dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. British Journal of Haematology, 2017, 176, 288-299.	1.2	43
97	Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment. European Journal of Internal Medicine, 2017, 42, 16-23.	1.0	76
98	Investigational drugs in phase I and phase II clinical trials for thalassemia. Expert Opinion on Investigational Drugs, 2017, 26, 793-802.	1.9	21
99	Recommendations regarding splenectomy in hereditary hemolytic anemias. Haematologica, 2017, 102, 1304-1313.	1.7	138
100	Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. American Journal of Hematology, 2017, 92, 1068-1078.	2.0	290
101	Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to plerixafor alone. Haematologica, 2017, 102, e120-e124.	1.7	33
102	Serum ferritin values between 300 and 800 ng/mL in nontransfusionâ€dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable. American Journal of Hematology, 2017, 92, E35-E37.	2.0	13
103	Treatment of hepatitis C virus infection with directâ€acting antiviral drugs is safe and effective in patients with hemoglobinopathies. American Journal of Hematology, 2017, 92, 1349-1355.	2.0	42
104	Decompensated Cirrhosis and Sickle Cell Disease: Case Reports and Review of the Literature. Hemoglobin, 2017, 41, 131-133.	0.4	5
105	Pulmonary dysfunction in thalassaemia major: is there any relationship with body iron stores?. British Journal of Haematology, 2017, 176, 309-314.	1.2	9
106	Oneâ€year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Pediatric Blood and Cancer, 2017, 64, 188-196.	0.8	24
107	The Role of Trabecular Bone Score and Hip Geometry in Thalassemia Major: A Neural Network Analysis. British Journal of Research, 2017, 04, .	0.1	1
108	Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia. International Journal of Molecular Sciences, 2017, 18, 2778.	1.8	20

#	Article	IF	Citations
109	Anti-TNF-Mediated Modulation of Prohepcidin Improves Iron Availability in Inflammatory Bowel Disease, in an IL-6-Mediated Fashion. Canadian Journal of Gastroenterology and Hepatology, 2017, 2017, 1-12.	0.8	25
110	New therapeutic targets in transfusion-dependent and -independent thalassemia. Hematology American Society of Hematology Education Program, 2017, 2017, 278-283.	0.9	35
111	Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. Drug Design, Development and Therapy, 2016, Volume 10, 4073-4078.	2.0	15
112	Deferasirox: an orphan drug for chronic iron overload in non-transfusion dependent thalassemia syndromes. Expert Opinion on Orphan Drugs, 2016, 4, 677-686.	0.5	2
113	A multicentre observational study for early diagnosis of Gaucher disease in patients with Splenomegaly and/or Thrombocytopenia. European Journal of Haematology, 2016, 96, 352-359.	1.1	34
114	A giant adrenal myelolipoma in a betaâ€thalassemia major patient: Does ineffective erythropoiesis play a role?. American Journal of Hematology, 2016, 91, 1281-1282.	2.0	5
115	Ferroportin expression and regulation in non-transfusion dependent thalassemia. Blood Cells, Molecules, and Diseases, 2016, 58, 26-28.	0.6	0
116	Xâ€chromosomal inactivation directly influences the phenotypic manifestation of Xâ€linked protoporphyria. Clinical Genetics, 2016, 89, 20-26.	1.0	25
117	Laboratory diagnosis of thalassemia. International Journal of Laboratory Hematology, 2016, 38, 32-40.	0.7	120
118	Standardization of MRI and Scintigraphic Scores for Assessing the Severity of Bone Marrow Involvement in Adult Patients With Type 1 Gaucher Disease. American Journal of Roentgenology, 2016, 206, 1245-1252.	1.0	11
119	When diagnostics meets translational research: detection of hemoglobin fractions in cellular lysates from in vitro erythroid cultures by Capillarys 2 Flex Piercing analyzer (Sebia). Translational Research, 2016, 169, 31-39.e4.	2.2	2
120	Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment. European Journal of Haematology, 2016, 96, 19-26.	1.1	27
121	Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Blood Cells, Molecules, and Diseases, 2016, 57, 23-29.	0.6	24
122	The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208.	1.7	67
123	Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins. Endocrine, 2016, 53, 551-557.	1.1	8
124	Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia. European Journal of Internal Medicine, 2016, 28, 91-96.	1.0	14
125	New insights into transfusion-related iron toxicity: Implications for the oncologist. Critical Reviews in Oncology/Hematology, 2016, 99, 261-271.	2.0	46
126	Disorders of Hemoglobin Synthesis: Pathophysiology and Diagnostic Evaluation. , 2016, , 29-37.		0

#	Article	IF	Citations
127	Myocardial and Hepatic Iron Overload Assessment by Region-Based and Pixel-Wise T2* Mapping Analysis. Journal of Computer Assisted Tomography, 2015, 39, 128-133.	0.5	6
128	Evidence of non-transferrin-bound iron in patients with ST-elevation myocardial infarction: relationship with microvascular obstruction and post-reperfusion myocardial hemorrhage. Journal of Cardiovascular Magnetic Resonance, 2015, 17, P118.	1.6	0
129	Treating hepatitis C in patients with hemoglobinopathies. Expert Opinion on Orphan Drugs, 2015, 3, 1267-1278.	0.5	0
130	Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: Kinetics of its appearance and potential predictive role in infectious complications. Leukemia Research, 2015, 39, 88-91.	0.4	18
131	The role of TMPRSS6 polymorphisms in iron deficiency anemia partially responsive to oral iron treatment. American Journal of Hematology, 2015, 90, 306-309.	2.0	32
132	Does TMPRSS6 RS855791 Polymorphism Contribute to Iron Deficiency in Treated Celiac Disease?. American Journal of Gastroenterology, 2015, 110, 200-202.	0.2	23
133	Hemoglobin level and morbidity in non-transfusion-dependent thalassemia. Blood Cells, Molecules, and Diseases, 2015, 55, 108-109.	0.6	20
134	Anemia in Clinical Practiceâ€"Definition and Classification: Does Hemoglobin Change With Aging?. Seminars in Hematology, 2015, 52, 261-269.	1.8	257
135	Molecular Basis of Î²-Thalassemia Intermedia in Erbil Province of Iraqi Kurdistan. Hemoglobin, 2015, 39, 178-183.	0.4	20
136	Anemia in elderly hospitalized patients: prevalence and clinical impact. Internal and Emergency Medicine, 2015, 10, 581-586.	1.0	53
137	Congenital erythropoietic porphyria linked to <scp>GATA</scp>1â€<scp>R</scp>216<scp>W</scp> mutation: challenges for diagnosis. European Journal of Haematology, 2015, 94, 491-497.	1.1	39
138	Anemia and splenomegaly: what lies behind?. Internal and Emergency Medicine, 2015, 10, 711-714.	1.0	0
139	Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood, 2015, 125, 3868-3877.	0.6	67
140	Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when <scp>MRI</scp> is unavailable in patients with nonâ€transfusionâ€dependent thalassaemia. British Journal of Haematology, 2015, 168, 284-290.	1.2	50
141	Deferasirox effect on renal haemodynamic parameters in patients with transfusionâ€dependent Î² thalassaemia. British Journal of Haematology, 2015, 168, 882-890.	1.2	27
142	Role of Non-Transferrin-Bound Iron in the pathogenesis of cardiotoxicity in patients with ST-elevation myocardial infarction assessed by Cardiac Magnetic Resonance Imaging. International Journal of Cardiology, 2015, 199, 326-332.	0.8	16
143	Hyponatremia: a challenge for internists. Internal and Emergency Medicine, 2015, 10, 973-976.	1.0	0
144	Growth Differentiation Factor 15 expression and regulation during erythroid differentiation in non-transfusion dependent thalassemia. Blood Cells, Molecules, and Diseases, 2015, 54, 26-28.	0.6	10

#	Article	IF	Citations
145	Management of Bone Disease in Gaucher Disease Type 1: Clinical Practice. Advances in Therapy, 2014, 31, 1197-1212.	1.3	29
146	Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica, 2014, 99, 811-820.	1.7	302
147	Resveratrol accelerates erythroid maturation by activation of FoxO3 and ameliorates anemia in beta-thalassemic mice. Haematologica, 2014, 99, 267-275.	1.7	89
148	Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. British Journal of Haematology, 2014, 167, 121-126.	1.2	69
149	Deferasirox for cardiac siderosis in Î²â€thalassaemia major: a multicentre, open label, prospective study. British Journal of Haematology, 2014, 167, 423-426.	1.2	7
150	Modulation of gamma globin genes expression by histone deacetylase inhibitors: an in vitro study. British Journal of Haematology, 2014, 165, 714-721.	1.2	18
151	Development of interactive algorithm for clinical management of acute events related to sickle cell disease in emergency department. Orphanet Journal of Rare Diseases, 2014, 9, 91.	1.2	14
152	Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up. Haematologica, 2014, 99, e17-e18.	1.7	14
153	Thalassemic osteopathy: A new marker of bone deposition. Blood Cells, Molecules, and Diseases, 2014, 52, 91-94.	0.6	10
154	Remission of autoimmune hyperthyroidism after chemotherapy for cancer. Internal and Emergency Medicine, 2014, 9, 109-111.	1.0	1
155	Bone disease in adult patients with Î²-thalassaemia major: a caseâ€“control study. Internal and Emergency Medicine, 2014, 9, 59-63.	1.0	11
156	An overview of current treatment strategies for Î²-thalassemia. Expert Opinion on Orphan Drugs, 2014, 2, 665-679.	0.5	8
157	A challenging diagnosis for potential fatal diseases: Recommendations for diagnosing acute porphyrias. European Journal of Internal Medicine, 2014, 25, 497-505.	1.0	34
158	Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): A status quo. Blood Cells, Molecules, and Diseases, 2014, 52, 88-90.	0.6	8
159	Prevalence and Risk Factors for Pulmonary Arterial Hypertension in a Large Group of Î²-Thalassemia Patients Using Right Heart Catheterization. Circulation, 2014, 129, 338-345.	1.6	101
160	Approaching low liver iron burden in chelated patients with nonâ€transfusionâ€dependent thalassemia: the safety profile of deferasirox. European Journal of Haematology, 2014, 92, 521-526.	1.1	17
161	Management of Non-Transfusion-Dependent Thalassemia: A Practical Guide. Drugs, 2014, 74, 1719-1729.	4.9	10
162	Validity of Î²-d-glucosidase activity measured in dried blood samples for detection of potential Gaucher disease patients. Clinical Biochemistry, 2014, 47, 1293-1296.	0.8	16

#	Article	IF	Citations
163	Priapism, an Emerging Complication in Î²-Thalassemia Intermedia Patients. Hemoglobin, 2014, 38, 351-354.	0.4	7
164	Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis <scp>C</scp> patients. Journal of Viral Hepatitis, 2014, 21, 416-423.	1.0	11
165	The Spectrum of Ocular Alterations in PatientsÂwith Î²-Thalassemia Syndromes Suggests a Pathology Similar to Pseudoxanthoma Elasticum. Ophthalmology, 2014, 121, 709-718.	2.5	37
166	Serum ferritin level and morbidity risk in transfusion-independent patients with Â-thalassemia intermedia: the ORIENT study. Haematologica, 2014, 99, e218-e221.	1.7	56
167	Thalassemic erythrocytes release microparticles loaded with hemichromes by redox activation of p72Syk kinase. Haematologica, 2014, 99, 570-578.	1.7	52
168	An Update on Thalassemia Intermedia. Journal Medical Libanais, 2014, 61, 175-182.	0.0	10
169	Antibodies reacting with Simian virus 40 mimotopes in serum samples from patients with thalassaemia major. Blood Transfusion, 2014, 12, 464-70.	0.3	4
170	Treating iron overload in patients with nonâ€transfusionâ€dependent thalassemia. American Journal of Hematology, 2013, 88, 409-415.	2.0	67
171	Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Annals of Hematology, 2013, 92, 1485-1493.	0.8	64
172	Deferasirox demonstrates a doseâ€dependent reduction in liver iron concentration and consistent efficacy across subgroups of nonâ€transfusionâ€dependent thalassemia patients. American Journal of Hematology, 2013, 88, 503-506.	2.0	16
173	Epidemiology of Clostridium difficile-associated disease in internal medicine wards in northern Italy. Internal and Emergency Medicine, 2013, 8, 717-723.	1.0	22
174	Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia. Expert Review of Hematology, 2013, 6, 495-509.	1.0	9
175	Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with Î²-thalassemia intermedia. Blood Cells, Molecules, and Diseases, 2013, 51, 35-38.	0.6	47
176	Assessment and management of iron overload in Î²â€thalassaemia major patients during the 21st century: a realâ€life experience from the <scp>I</scp>talian <scp>W</scp>ebthal project. British Journal of Haematology, 2013, 161, 872-883.	1.2	31
177	Challenges in dealing with a cirrhotic patient. Internal and Emergency Medicine, 2013, 8, 161-164.	1.0	0
178	Prolonged PT and aPTT in a patient with severe proteinuria. Internal and Emergency Medicine, 2013, 8, 611-614.	1.0	0
179	A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrology Dialysis Transplantation, 2013, 28, 1733-1743.	0.4	47
180	Iron overload in Î²-thalassemia intermedia. Current Opinion in Hematology, 2013, 20, 187-192.	1.2	42

#	Article	IF	Citations
181	Very high frequency of <scp>TMPRSS6</scp> gene variations in iron deficiency anaemia of patients with polyendocrine autoimmune syndromes: more than a casual association?. British Journal of Haematology, 2013, 161, 147-150.	1.2	3
182	Mosaic segmental uniparental isodisomy and progressive clonal selection: a common mechanism of late onset Â-thalassemia major. Haematologica, 2013, 98, 691-695.	1.7	11
183	Clinical experience with fetal hemoglobin induction therapy in patients with Î²-thalassemia. Blood, 2013, 121, 2199-2212.	0.6	154
184	Altered iron homeostasis in an animal model of hypertensive nephropathy. Journal of Hypertension, 2013, 31, 2259-2269.	0.3	7
185	Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: A closer look at the role of siderosis. Annals of Hepatology, 2013, 12, 142-146.	0.6	46
186	Transcranial Color Doppler Sonography and Magnetic Resonance Imaging In Adult Patients With Sickle Cell Disease. Blood, 2013, 122, 2245-2245.	0.6	1
187	Deferasiroxâ€“Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION). Blood, 2013, 122, 2257-2257.	0.6	5
188	Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. Blood Transfusion, 2013, 11, 108-22.	0.3	17
189	Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis. Annals of Hepatology, 2013, 12, 142-6.	0.6	18
190	The Thalassemias. , 2012, , 1060-1066.		0
191	Thyroid Cancer in Î²-Thalassemia. Hemoglobin, 2012, 36, 407-408.	0.4	5
192	Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with Â-thalassemia major. Haematologica, 2012, 97, 842-848.	1.7	122
193	Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence inÎ²-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial. Anemia, 2012, 2012, 1-10.	0.5	52
194	Î²-Thalassemia: New Therapeutic Modalities, Genetics, Complications, and Quality of Life. Anemia, 2012, 2012, 1-1.	0.5	38
195	Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood, 2012, 120, 970-977.	0.6	115
196	How I treat transfusional iron overload. Blood, 2012, 120, 3657-3669.	0.6	168
197	Does absolute excess of alpha chains compromise the benefit of splenectomy in patients with thalassemia intermedia?. Haematologica, 2012, 97, 151-153.	1.7	5
198	Recent advances and treatment challenges in patients with non-transfusion-dependent thalassemia. Blood Reviews, 2012, 26, S1-S2.	2.8	13

#	Article	IF	Citations
199	Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Reviews, 2012, 26, S16-S19.	2.8	105
200	Hypercoagulability in non-transfusion-dependent thalassemia. Blood Reviews, 2012, 26, S20-S23.	2.8	44
201	Contemporary approaches to treatment of beta-thalassemia intermedia. Blood Reviews, 2012, 26, S24-S27.	2.8	40
202	Seven novel genetic mutations within the 5â€²UTR and the housekeeping promoter of HMBS gene responsible for the non-erythroid form of acute intermittent porphyria. Blood Cells, Molecules, and Diseases, 2012, 49, 147-151.	0.6	12
203	Minimal disease activity in Gaucher disease: Criteria for definition. Molecular Genetics and Metabolism, 2012, 107, 521-525.	0.5	4
204	Abnormal Fundus Autofluorescence Results of Patients in Long-term Treatment with Deferoxamine. Ophthalmology, 2012, 119, 1693-1700.	2.5	39
205	Hypercoagulability in Î²-thalassemia: a status quo. Expert Review of Hematology, 2012, 5, 505-512.	1.0	70
206	Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with Î²-thalassemia intermedia. Blood Cells, Molecules, and Diseases, 2012, 49, 136-139.	0.6	42
207	What does acute dyspnea hide?. Internal and Emergency Medicine, 2012, 7, 353-358.	1.0	1
208	Fetal hemoglobin levels and morbidity in untransfused patients with Î²-thalassemia intermedia. Blood, 2012, 119, 364-367.	0.6	85
209	Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients. Annals of Hematology, 2012, 91, 1443-1449.	0.8	41
210	Neridronate improves bone mineral density and reduces back pain in Î²â€thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallelâ€arm, openâ€label study. British Journal of Haematology, 2012, 158, 274-282.	1.2	36
211	Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4â€“5Âyears. British Journal of Haematology, 2012, 158, 528-538.	1.2	33
212	Erythropoietin in Friedreich ataxia: No effect on frataxin in a randomized controlled trial. Movement Disorders, 2012, 27, 446-449.	2.2	57
213	Serum Ferritin Levels and Morbidity in Î²-Thalassemia Intermedia: A 10-Year Cohort Study. Blood, 2012, 120, 1021-1021.	0.6	11
214	Evaluation of the 5 Mg/g Liver Iron Concentration Threshold and Its Association with Vascular and Endocrine/Bone Morbidity in Î²-Thalassemia Intermedia. Blood, 2012, 120, 1024-1024.	0.6	1
215	Two-Year Renal Hemodynamic Effects of Deferasirox in Patients with Transfusion-Dependent Î²-Thalassemia. Blood, 2012, 120, 3257-3257.	0.6	2
216	Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA). Blood, 2012, 120, 3258-3258.	0.6	3

#	Article	IF	Citations
217	An update on iron chelation therapy. Blood Transfusion, 2012, 10, 411-22.	0.3	164
218	A Hepcidin Inhibitor Mobilizes Iron for Incorporation Into Red Blood Cells in an Adenine-Induced Chronic Kidney Disease Model in Rats.. Blood, 2012, 120, 2082-2082.	0.6	0
219	Oxidative stress modulates heme synthesis and induces peroxiredoxin-2 as a novel cytoprotective response in Â-thalassemic erythropoiesis. Haematologica, 2011, 96, 1595-1604.	1.7	63
220	Improvement in Liver Pathology of Patients With Î²-Thalassemia Treated With Deferasirox for at Least 3 Years. Gastroenterology, 2011, 141, 1202-1211.e3.	0.6	73
221	Risk factors for pulmonary hypertension in patients with Î² thalassemia intermedia. European Journal of Internal Medicine, 2011, 22, 607-610.	1.0	56
222	Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells, Molecules, and Diseases, 2011, 47, 166-175.	0.6	50
223	Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with Î² thalassemia intermedia. Blood Cells, Molecules, and Diseases, 2011, 47, 232-234.	0.6	55
224	Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes. PLoS ONE, 2011, 6, e23109.	1.1	95
225	Optimal management of Î² thalassaemia intermedia. British Journal of Haematology, 2011, 152, 512-523.	1.2	187
226	An unusual febrile nonhemolytic reaction occurred after transfusion in a thalassemia major patient with asymptomatic Plasmodium falciparum infection. Transfusion, 2011, 51, 469-472.	0.8	3
227	Congenital Dyserythropoietic Anemia Type II: molecular analysis and expression of the SEC23B Gene. Orphanet Journal of Rare Diseases, 2011, 6, 89.	1.2	17
228	A reappraisal of Gaucher diseaseâ€"diagnosis and disease management algorithms. American Journal of Hematology, 2011, 86, 110-115.	2.0	135
229	Changing patterns of splenectomy in transfusionâ€dependent thalassemia patients. American Journal of Hematology, 2011, 86, 808-810.	2.0	32
230	Thrombosis and Sickle Cell Disease. Seminars in Thrombosis and Hemostasis, 2011, 37, 226-236.	1.5	146
231	Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood, 2011, 118, 884-893.	0.6	181
232	A highly conserved SOX6 double binding site mediates SOX6 gene downregulation in erythroid cells. Nucleic Acids Research, 2011, 39, 486-501.	6.5	76
233	Clinical management of cardiovascular complications in patients with thalassaemia major: a large observational multicenter study. European Journal of Echocardiography, 2011, 12, 242-246.	2.3	16
234	Elevated liver iron concentration is a marker of increased morbidity in patients with Â thalassemia intermedia. Haematologica, 2011, 96, 1605-1612.	1.7	153

#	Article	IF	Citations
235	Continued improvement in myocardial T2* over two years of deferasirox therapy in Â-thalassemia major patients with cardiac iron overload. Haematologica, 2011, 96, 48-54.	1.7	70
236	Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study. Blood, 2011, 118, 902-902.	0.6	2
237	Improvement of Cardiac Function and Cardiac Volumes in Patients Treated with Deferasirox. Blood, 2011, 118, 2159-2159.	0.6	2
238	Efficacy of deferasirox in reducing and preventing cardiac iron overload in Î²-thalassemia. Blood, 2010, 115, 2364-2371.	0.6	168
239	Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Annals of Hematology, 2010, 89, 585-589.	0.8	55
240	Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major. Annals of Hematology, 2010, 89, 1207-1213.	0.8	40
241	Selective toxicity of dihydroartemisinin on human CD34+ erythroid cell differentiation. Toxicology, 2010, 276, 128-134.	2.0	27
242	An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial. Advances in Therapy, 2010, 27, 533-546.	1.3	11
243	Hepcidin mutation in a Î²-thalassemia major patient with persistent severe iron overload despite chelation therapy. Internal and Emergency Medicine, 2010, 5, 83-85.	1.0	3
244	Porphyrias at a glance: diagnosis and treatment. Internal and Emergency Medicine, 2010, 5, 73-80.	1.0	18
245	Correction of Î²â€thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Molecular Medicine, 2010, 2, 315-328.	3.3	82
246	Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusionâ€independent thalassemia intermedia compared to regularly transfused thalassemia major patients. American Journal of Hematology, 2010, 85, 288-290.	2.0	61
247	Transient elastography in the assessment of liver fibrosis in adult thalassemia patients. American Journal of Hematology, 2010, 85, 564-568.	2.0	40
248	Renal complications in transfusion-dependent beta thalassaemia. Blood Reviews, 2010, 24, 239-244.	2.8	70
249	Ageâ€related complications in treatmentâ€naÃ¯ve patients with thalassaemia intermedia. British Journal of Haematology, 2010, 150, 486-489.	1.2	100
250	Genetic variability of TMPRSS6 and its association with iron deficiency anaemia. British Journal of Haematology, 2010, 151, 281-284.	1.2	33
251	Redefining thalassemia as a hypercoagulable state. Annals of the New York Academy of Sciences, 2010, 1202, 231-236.	1.8	78
252	The pituitaryâ€“adrenal axis in adult thalassaemic patients. European Journal of Endocrinology, 2010, 162, 43-48.	1.9	23

#	Article	IF	Citations
253	Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica, 2010, 95, 557-566.	1.7	260
254	Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood, 2010, 115, 1886-1892.	0.6	315
255	Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood, 2010, 116, 2875-2883.	0.6	79
256	A validated disease severity scoring system for adults with type 1 Gaucher disease. Genetics in Medicine, 2010, 12, 44-51.	1.1	66
257	EPO Receptor Gain-of-Function Causes Hereditary Polycythemia, Alters CD34+ Cell Differentiation and Increases Circulating Endothelial Precursors. PLoS ONE, 2010, 5, e12015.	1.1	23
258	Hepcidin Levels and Their Determinants In Different Types of Myelodysplastic Syndromes. Blood, 2010, 116, 4250-4250.	0.6	0
259	Pregnant women affected by thalassemia major: a controlled study of traits and personality. Journal of Research in Medical Sciences, 2010, 15, 100-6.	0.4	6
260	Update on the use of deferasirox in the management of iron overload. Therapeutics and Clinical Risk Management, 2009, 5, 857.	0.9	27
261	A novel large deletion and three polymorphisms in the FECH gene associated with erythropoietic protoporphyria. Clinical Chemistry and Laboratory Medicine, 2009, 47, 44-6.	1.4	5
262	Multiplex ligation-dependent probe amplification: a novel approach for genetic diagnosis of Porphyria. Journal of Human Genetics, 2009, 54, 479-487.	1.1	13
263	Cholelithiasis in thalassemia major. European Journal of Haematology, 2009, 82, 22-25.	1.1	29
264	High nontransferrin bound iron levels and heart disease in thalassemia major. American Journal of Hematology, 2009, 84, 29-33.	2.0	128
265	Mutation analysis of hepcidin and ferroportin genes in Italian prospective blood donors with iron overload. American Journal of Hematology, 2009, 84, 592-593.	2.0	7
266	Paralytic Ileus and Liver Failureâ€"An Unusual Presentation of Advanced Erythropoietic Protoporphyria. Digestive Diseases and Sciences, 2009, 54, 411-415.	1.1	12
267	The acute porphyrias: a diagnostic and therapeutic challenge in internal and emergency medicine. Internal and Emergency Medicine, 2009, 4, 297-308.	1.0	31
268	Levels of nonâ€transferrinâ€bound iron as an index of iron overload in patients with thalassaemia intermedia. British Journal of Haematology, 2009, 146, 569-572.	1.2	66
269	Pregnancy and risk of venous thromboembolism in developing countries. British Journal of Haematology, 2009, 146, 691-692.	1.2	0
270	Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. British Journal of Haematology, 2009, 147, 634-640.	1.2	71

#	Article	IF	Citations
271	Efficacy and safety of deferasirox doses of >30â€ƒmg/kg per d in patients with transfusionâ€dependent anaemia and iron overload. British Journal of Haematology, 2009, 147, 752-759.	1.2	101
272	Assessment of Mitoxantroneâ€Induced Cardiotoxicity in Patients with Multiple Sclerosis: A Tissue Doppler Echocardiographic Analysis. Echocardiography, 2009, 26, 397-402.	0.3	10
273	Neuropsychological functions and metabolic aspects in subclinical hypothyroidism: The effects of l-thyroxine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 854-859.	2.5	23
274	Oral Iron Chelators. Annual Review of Medicine, 2009, 60, 25-38.	5.0	88
275	Thalassaemia Intermedia: an Update. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009004.	0.5	34
276	Insight onto the Pathophysiology and Clinical Complications of Thalassemia Intermedia. Hemoglobin, 2009, 33, S145-S159.	0.4	33
277	Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone. Hemoglobin, 2009, 33, S58-S69.	0.4	33
278	Case study on monoclonal gammopathy of undetermined significance/multiple myeloma. Clinical Therapeutics, 2009, 31, S181.	1.1	0
279	Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. Haematologica, 2009, 94, 1520-1527.	1.7	74
280	Efficacy and Safety of Deferasirox (ExjadeÂ®) in Î²-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.. Blood, 2009, 114, 4062-4062.	0.6	4
281	Efficacy and Safety of Deferasirox (ExjadeÂ®) in Patients with Î²-Thalassemia Major Treated for up to 5 Years.. Blood, 2009, 114, 4063-4063.	0.6	5
282	Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox in Non-Transfusion-Dependent Thalassemia Patients with Iron Overload.. Blood, 2009, 114, 5111-5111.	0.6	1
283	COAGULOPATHY IN BETA-THALASSEMIA: CURRENT UNDERSTANDING AND FUTURE PERSPECTIVES. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009029.	0.5	19
284	Relative response of patients with myelodysplastic syndromes and other transfusionâ€dependent anaemias to deferasirox (ICL670): a 1â€yr prospective study. European Journal of Haematology, 2008, 80, 168-176.	1.1	210
285	Unusual association of a pituitary adenoma and a neurological emergency: case report and diagnostic steps. Internal and Emergency Medicine, 2008, 3, 297-300.	1.0	0
286	Psychosocial aspects and psychiatric disorders in young adult with thalassemia major. Internal and Emergency Medicine, 2008, 3, 339-343.	1.0	79
287	Introduction. Blood Reviews, 2008, 22, S13.	2.8	2
288	Long-term efficacy and safety of deferasirox. Blood Reviews, 2008, 22, S35-S41.	2.8	69

#	Article	IF	Citations
289	Myocardial involvement during the early course of type 2 diabetes mellitus: usefulness of Myocardial Performance Index. Cardiovascular Ultrasound, 2008, 6, 27.	0.5	17
290	Stroke in thalassemia: A dilemma. American Journal of Hematology, 2008, 83, 343-343.	2.0	18
291	Thalassemia and hypercoagulability. Blood Reviews, 2008, 22, 283-292.	2.8	143
292	Bone demineralization in adult thalassaemic patients: contribution of GH and IGFâ€Ì at different skeletal sites. Clinical Endocrinology, 2008, 69, 202-207.	1.2	36
293	Costs, quality of life, treatment satisfaction and compliance in patients with Î²-thalassemia major undergoing iron chelation therapy: the ITHACA study. Current Medical Research and Opinion, 2008, 24, 1905-1917.	0.9	101
294	Erythroid differentiation and maturation from peripheral CD34+ cells in liquid culture: Cellular and molecular characterization. Blood Cells, Molecules, and Diseases, 2008, 40, 148-155.	0.6	45
295	A 10376Âbp deletion of FECH gene responsible for erythropoietic protoporphyria. Blood Cells, Molecules, and Diseases, 2008, 40, 233-236.	0.6	7
296	Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen. Journal of Clinical Pharmacology, 2008, 48, 428-435.	1.0	36
297	Glucose-6-phosphate dehydrogenase deficiency. Lancet, The, 2008, 371, 64-74.	6.3	1,223
298	Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica, 2008, 93, 741-752.	1.7	182
299	Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opinion on Pharmacotherapy, 2008, 9, 2391-2402.	0.9	40
300	Challenges Associated With Prolonged Survival of Patients With Thalassemia: Transitioning From Childhood to Adulthood. Pediatrics, 2008, 121, e1426-e1429.	1.0	34
301	Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica, 2008, 93, 1584-1586.	1.7	113
302	Ethical Issues and Risk/Benefit Assessment of Iron Chelation Therapy: Advances with Deferiprone/deferoxamine Combinations and Concerns about the Safety, Efficacy and Costs of Deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1â€“2):1â€“15.]. Hemoglobin, 2008, 32, 601-607.	0.4	8
303	Current Status in Iron Chelation in Hemoglobinopathies. Current Molecular Medicine, 2008, 8, 663-674.	0.6	31
304	Pregnancy outcome in patients with Â-thalassemia intermedia at two tertiary care centers, in Beirut and Milan. Haematologica, 2008, 93, 1586-1587.	1.7	54
305	A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica, 2008, 93, 1211-1218.	1.7	55
306	Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in Î²-thalassemia. Blood, 2008, 112, 875-885.	0.6	146

#	Article	IF	Citations
307	Effect of Deferasirox (ExjadeÂ®) on Labile Plasma Iron Levels in Heavily Iron-Overloaded Patients with Transfusion-Dependent Anemias Enrolled in the Large-Scale, Prospective 1-Year EPIC Trial. Blood, 2008, 112, 3881-3881.	0.6	14
308	Beta-thalassemia Intermedia: An Overview. Pediatric Annals, 2008, 37, 322-8.	0.3	12
309	Red Blood Cell Enzyme Disorders: An Overview. Pediatric Annals, 2008, 37, 303-10.	0.3	8
310	Identification of Three Novel Substitutions in the Erythroid Promoter of the HMBS Gene: A New Erythroid Variant of Human Acute Intermittent Porphyria?. Blood, 2008, 112, 4574-4574.	0.6	3
311	Coagulation in the Pathophysiology of Hemolytic Anemias. Hematology American Society of Hematology Education Program, 2007, 2007, 74-78.	0.9	92
312	Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood, 2007, 109, 362-364.	0.6	78
313	Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with Î²-thalassemia. Clinical Therapeutics, 2007, 29, 909-917.	1.1	123
314	Hematologic and Hemato-Oncologic Aspects of Gaucher Disease. Clinical Therapeutics, 2007, 29, S88-S90.	1.1	0
315	K-CL co-transport plays an important role in normal and Â thalassemic erythropoiesis. Haematologica, 2007, 92, 1319-1326.	1.7	18
316	Expression of the ?-globin gene is sustained by the cAMP-dependent pathway in ?-thalassaemia. British Journal of Haematology, 2007, 138, 382-395.	1.2	28
317	Recommendations for the management of the haematological and oncoâ€haematological aspects of Gaucher disease¹. British Journal of Haematology, 2007, 138, 676-686.	1.2	81
318	Î²â€Thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. British Journal of Haematology, 2007, 139, 3-13.	1.2	188
319	Growth hormone deficiency (GHD) in adult thalassaemic patients. Clinical Endocrinology, 2007, 67, 790-795.	1.2	38
320	Long-Term Treatment with Deferasirox (ExjadeÂ®, ICL670), a Once-Daily Oral Iron Chelator, Is Effective in Patients with Transfusion-Dependent Anemias.. Blood, 2007, 110, 2777-2777.	0.6	10
321	Impact of Dose Adjustments on Serum Ferritin (SF) Levels during Long-Term Treatment with Once-Daily, Oral Deferasirox (ExjadeÂ®, ICL670).. Blood, 2007, 110, 2778-2778.	0.6	3
322	Evaluation of Deferasirox (ExjadeÂ®, ICL670) Therapy in Patients with Transfusional Iron Overload Who Achieve Serum Ferritin (SF) â‰¤1000 ng/mL in Long-Term Studies.. Blood, 2007, 110, 3795-3795.	0.6	6
323	Exjadeï¿½ (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Therapeutics and Clinical Risk Management, 2007, 3, 291-299.	0.9	65
324	Gender Differences in Iron Overload and Left Ventricular Function in a Cohort of Thalassemia Major Patients: A Prospective Study of a Single Italian Center Using Cardiovascular Magnetic Resonance.. Blood, 2007, 110, 3819-3819.	0.6	0

#	Article	IF	Citations
325	cAMP differentially regulates Î³-globin gene expression in erythroleukemic cells and primary erythroblasts through c-Myb expression. Biochemical and Biophysical Research Communications, 2006, 344, 1038-1047.	1.0	33
326	Thalassemia intermedia: Revisited. Blood Cells, Molecules, and Diseases, 2006, 37, 12-20.	0.6	269
327	A large deletion on chromosome 11 in acute intermittent porphyria. Blood Cells, Molecules, and Diseases, 2006, 37, 50-54.	0.6	8
328	Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood, 2006, 107, 3733-3737.	0.6	338
329	A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood, 2006, 107, 3455-3462.	0.6	636
330	Deferasirox: a novel, once-daily oral iron chelator. Therapy: Open Access in Clinical Medicine, 2006, 3, 453-460.	0.2	2
331	Co-existence of two functional mutations on the same allele of the human ferrochelatase gene in erythropoietic protoporphyria. Clinical Genetics, 2006, 71, 84-88.	1.0	16
332	A woman with black urine. British Journal of Haematology, 2006, 137, 061127011144004-???.	1.2	1
333	Modification of sialidase levels and sialoglycoconjugate pattern during erythroid and erytroleukemic cell differentiation. Glycoconjugate Journal, 2006, 24, 67-79.	1.4	17
334	Changes in erythropoiesis, iron metabolism and oxidative stress after half-marathon. Internal and Emergency Medicine, 2006, 1, 30-34.	1.0	18
335	Unusual severe development of common B lymphoblastic leukemia in Gaucher disease type I. American Journal of Hematology, 2006, 81, 383-384.	2.0	3
336	Removing the Burdenâ€"Iron Overload and Deferasirox (ICL670). Oncology & Hematology Review, 2006, 00, 67.	0.2	1
337	Ineffective Erythropoiesis in Î²-Thalassemia Is Characterized by Enhanced Survival Mechanisms That Reduce P21-Mediated Cell Death.. Blood, 2006, 108, 649-649.	0.6	0
338	Deferasirox: a novel, once-daily oral iron chelator. Therapy: Open Access in Clinical Medicine, 2006, 3, 453-460.	0.2	0
339	Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica, 2006, 91, 873-80.	1.7	210
340	Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thrombosis and Haemostasis, 2006, 96, 488-91.	1.8	86
341	Coagulation and Splenectomy: An Overview. Annals of the New York Academy of Sciences, 2005, 1054, 317-324.	1.8	110
342	Exercise capacity in patients with beta-thalassaemia intermedia. British Journal of Haematology, 2005, 131, 278-281.	1.2	12

#	Article	IF	Citations
343	A point mutation affecting an SP1 binding site in the promoter of the ferrochelatase gene impairs gene transcription and causes erythropoietic protoporphyria. Experimental Hematology, 2005, 33, 584-591.	0.2	20
344	Overcoming the challenge of patient compliance with iron chelation therapy. Seminars in Hematology, 2005, 42, S19-S21.	1.8	40
345	Iron-chelating therapy with the new oral agent ICL670 (ExjadeÂ®). Best Practice and Research in Clinical Haematology, 2005, 18, 289-298.	0.7	78
346	Two Functional Mutations in cis of the Ferrochelatase Gene (FECH) Cause Erythropoietic Protoporphyria (EPP).. Blood, 2005, 106, 3544-3544.	0.6	0
347	Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica, 2005, 90, 452-8.	1.7	91
348	Purging iron from the heart. British Journal of Haematology, 2004, 125, 545-551.	1.2	34
349	Hepatocellular carcinoma in the thalassaemia syndromes. British Journal of Haematology, 2004, 124, 114-117.	1.2	147
350	Intrathoracic Masses Due to Extramedullary Hematopoiesis. American Journal of the Medical Sciences, 2004, 328, 299-303.	0.4	26
351	Molecular Analysis of Alpha Hemoglobin Stabilizing Protein (AHSP) in Caucasian Patients with different Beta-Thalassemia Phenotypes.. Blood, 2004, 104, 3770-3770.	0.6	5
352	Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica, 2004, 89, 1179-86.	1.7	49
353	Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica, 2004, 89, 1187-93.	1.7	772
354	Î²-THALASSEMIA INTERMEDIA FROM SOUTHERN IRAN: IVS-II-1 (Gâ†'A) IS THE PREVALENT THALASSEMIA INTERMEDIA ALLELE. Hemoglobin, 2002, 26, 147-154.	0.4	44
355	Long-term treatment with oral sildenafil in a thalassemic patient with pulmonary hypertension. Blood, 2002, 100, 1516-1517.	0.6	54
356	Hematologically Important Mutations: Acute Intermittent Porphyria. Blood Cells, Molecules, and Diseases, 2002, 28, 5-12.	0.6	9
357	The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. British Journal of Haematology, 2002, 118, 330-336.	1.2	192
358	Tc-99m Sulphur Colloid Scintigraphy in the Assessment of Residual Splenic Tissue after Splenectomy. Clinical Radiology, 2001, 56, 1-4.	0.5	21
359	Membrane-bound iron contributes to oxidative damage of Î²-thalassaemia intermedia erythrocytes. British Journal of Haematology, 2001, 112, 48-50.	1.2	68
360	Non-Transferrin-Bound Iron in Alcohol Abusers. Alcoholism: Clinical and Experimental Research, 2001, 25, 1494-1499.	1.4	43

#	Article	IF	Citations
361	Non-Transferrin-Bound Iron in Alcohol Abusers. Alcoholism: Clinical and Experimental Research, 2001, 25, 1494-1499.	1.4	16
362	Molecular analysis of the hydroxymethylbilane synthase (HMBS) gene in Italian patients with acute intermittent porphyria: Report of four novel mutations. Human Mutation, 2000, 15, 480-480.	1.1	10
363	Oral Isobutyramide Therapy in Patients with Thalassemia Intermedia: Results of a Phase II Open Study. Blood Cells, Molecules, and Diseases, 2000, 26, 105-111.	0.6	41
364	Non-transferrin-bound iron, iron-related oxidative stress and lipid peroxidation in Î²-thalassemia intermedia. Transfusion Science, 2000, 23, 245-246.	0.6	22
365	Chronic non-spherocytic haemolytic disorders associated with glucose-6-phosphate dehydrogenase variants. Best Practice and Research in Clinical Haematology, 2000, 13, 39-55.	0.7	47
366	Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?. The Hematology Journal, 2000, 1, 153-158.	2.0	62
367	Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. British Journal of Haematology, 2000, 111, 467-473.	1.2	244
368	Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. British Journal of Haematology, 2000, 111, 461-466.	1.2	66
369	Metabolic indicators of oxidative stress correlate with haemichrome attachment to membrane, band 3 aggregation and erythrophagocytosis in Î²-thalassaemia intermedia. British Journal of Haematology, 1999, 104, 504-512.	1.2	76
370	Carbohydrate-deficient transferrin, a sensitive marker of chronic alcohol abuse, is highly influenced by body iron. Hepatology, 1999, 29, 658-663.	3.6	74
371	Butyrate Trialsa. Annals of the New York Academy of Sciences, 1998, 850, 110-119.	1.8	12
372	Survival and Disease Complications in Thalassemia Major. Annals of the New York Academy of Sciences, 1998, 850, 227-231.	1.8	312
373	High prevalence of the His63Asp HFE mutation in italian patients with porphyria cutanea tarda. Hepatology, 1998, 27, 181-184.	3.6	195
374	cDNA Cloning and Functional Characterization of the Mouse Ca2+-gated K+ Channel, mIK1. Journal of Biological Chemistry, 1998, 273, 21542-21553.	1.6	183
375	A Multicenter Prospective Study on the Risk of Acquiring Liver Disease in Antiâ€“Hepatitis C Virus Negative Patients Affected From Homozygous Î²-Thalassemia. Blood, 1998, 92, 3460-3464.	0.6	71
376	A Multicenter Prospective Study on the Risk of Acquiring Liver Disease in Antiâ€“Hepatitis C Virus Negative Patients Affected From Homozygous Î²-Thalassemia. Blood, 1998, 92, 3460-3464.	0.6	2
377	The expression of uridine diphosphate glucuronosyltransferase gene is a major determinant of bilirubin level in heterozygous beta-thalassaemia and in glucose-6-phosphate dehydrogenase deficiency. British Journal of Haematology, 1997, 99, 437-439.	1.2	87
378	Genetic hemochromatosis in Italian patients with prophyria cutanea tarda: possible explanation for iron overload. Journal of Hepatology, 1996, 24, 564-569.	1.8	47

#	Article	IF	Citations
379	Carbohydrate-Deficient Transferrin in Alcohol and Nonalcohol Abusers with Liver Disease. Alcoholism: Clinical and Experimental Research, 1995, 19, 1525-1527.	1.4	32
380	Molecular characterisation of the glucose-6-phosphate dehydrogenase (G6PD) Ferrara II variant. Human Genetics, 1995, 95, 440-442.	1.8	15
381	G6PD Ferrara I has the same two mutations as G6PD A(-) but a distinct biochemical phenotype. Human Genetics, 1994, 93, 139-142.	1.8	15
382	Biochemical and molecular characterization of a new sporadic glucose-6-phosphate dehydrogenase variant described in Italy: G6PD Modena. British Journal of Haematology, 1994, 87, 209-211.	1.2	8
383	Molecular characterisation of an Italian G6PD variant responsible for chronic nonâ€spherocytic haemolytic anaemia. Clinical Genetics, 1994, 46, 357-359.	1.0	4
384	Iron status in red cell pyruvate kinase deficiency: study of Italian cases. British Journal of Haematology, 1993, 83, 485-490.	1.2	62
385	Linkage analysis of 6p21 polymorphic markers and the hereditary hemochromatosis: localization of the gene centromeric to HLA-F. Human Molecular Genetics, 1993, 2, 571-576.	1.4	40
386	Uremic Inhibitors of Erythropoiesis: A Study during Treatment with Recombinant Human Erythropoietin. American Journal of Nephrology, 1992, 12, 9-13.	1.4	6
387	Functional roles of the ferritin receptors of human liver, hepatoma, lymphoid and erythroid cells. Journal of Inorganic Biochemistry, 1992, 47, 219-227.	1.5	64
388	Hepatitis C virus and porphyria cutanea tarda: Evidence of a strong association. Hepatology, 1992, 16, 1322-1326.	3.6	298
389	Binding and suppressive activity of human recombinant ferritins on erythroid cells. American Journal of Hematology, 1992, 39, 264-268.	2.0	15
390	Association of Hereditary Spherocytosis and Idiopathic Hemochromatosis: A Synergistic Effect in Determining Iron Overload. American Journal of Clinical Pathology, 1986, 86, 645-649.	0.4	35
391	Nonâ€Specific Iron in Patients with Betaâ€Thalassaemia Trait and Chronic Active Hepatitis. Scandinavian Journal of Haematology, 1981, 26, 161-167.	0.0	11
392	Thalassemia Is Paradoxically Associated with a Reduced Risk of In-Hospital Complications and Mortality in COVID-19: Data from an International Registry. SSRN Electronic Journal, 0, , .	0.4	0